Recent patents on anti-cancer drug discovery
Mir-338-3p Increases the Sensitivity to Oxaliplatin via Reversing Epithelialmesenchymal Transition in Hepatocellular Carcinoma Cells.
Chuan Huang, Zhenguang Huang, Jun Luo, Meiyi Wu, Kaining Cai, Ruiqiang Zhao, Yan Wen
Published: 202610.2174/0115748928408751251113182005
Abstract
OBJECTIVE: Oxaliplatin (OXA) is commonly used in combination therapy for patients with advanced hepatocellular carcinoma. While the emergence of acquired resistance dramatically reduces its efficacy. It was previously found that the sensitivity of dr…
Preview only. Read the full abstract at the source